Co-Diagnostics (C970) Stock Statistics & Valuation Metrics
Total Valuation
Co-Diagnostics has a market cap or net worth of EUR 2.89M. The enterprise value is EUR 11.51M.
- Market Cap
- EUR 2.89M
- Enterprise Value
- EUR 11.51M
Share Statistics
Co-Diagnostics has 8,822,648 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,822,648
- Owned by Insiders
- 1.10%
- Owned by Institutions
- 5.35%
Financial Efficiency
Co-Diagnostics’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -138.31%.
- Return on Equity (ROE)
- -2.27
- Return on Assets (ROA)
- -1.90
- Return on Invested Capital (ROIC)
- -138.31%
- Return on Capital Employed (ROCE)
- -1.48
- Revenue Per Employee
- 5,412.948
- Profits Per Employee
- -407.79K
- Employee Count
- 115
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.22
Valuation Ratios
The current PE Ratio of Co-Diagnostics is -0.01. Co-Diagnostics’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 3.79
- PB Ratio
- 0.12
- Price to FCF
- -0.10
- Price to Operating Cash Flow
- -0.06
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Co-Diagnostics had revenue of 622.49K and earned -46.90M in profits. Earnings per share was -35.25.
- Revenue
- 622.49K
- Gross Profit
- 400.11K
- Operating Income
- -31.28M
- Pretax Income
- -48.51M
- Net Income
- -46.90M
- EBITDA
- -47.41M
- Earnings Per Share (EPS)
- -35.25
Cash Flow
In the last 12 months, operating cash flow was -27.10M and capital expenditures -367,372, giving a free cash flow of -27.47M billion.
- Operating Cash Flow
- -27.10M
- Free Cash Flow
- -27.47M
- Free Cash Flow per Share
- -6.37
Dividends & Yields
Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1005.72%
- Earnings Yield
- -2977.35%
Stock Price Statistics
- Beta
- 0.83
- 52-Week Price Change
- -54.50%
- 50-Day Moving Average
- 5.16
- 200-Day Moving Average
- 5.16
- Relative Strength Index (RSI)
- 28.44
- Average Volume (3m)
- ―
Important Dates
Co-Diagnostics upcoming earnings date is Nov 12, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Co-Diagnostics as a current ratio of 3.87, with Debt / Equity ratio of 5.99%
- Current Ratio
- 3.87
- Quick Ratio
- 3.59
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 0.22
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Co-Diagnostics has paid -1.62M in taxes.
- Income Tax
- -1.62M
- Effective Tax Rate
- 0.03
Enterprise Valuation
Co-Diagnostics EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.03.
- EV to Sales
- 1.22
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.03
- EV to Operating Cash Flow
- -0.03
Balance Sheet
Co-Diagnostics has EUR 3.65M in cash and marketable securities with EUR 1.80M in debt, giving a net cash position of EUR 1.85M billion.
- Cash & Marketable Securities
- EUR 3.65M
- Total Debt
- EUR 1.80M
- Net Cash
- EUR 1.85M
- Net Cash Per Share
- EUR 0.21
- Tangible Book Value Per Share
- EUR 1.27
Margins
Gross margin is 8.07%, with operating margin of -4170.14%, and net profit margin of -6523.04%.
- Gross Margin
- 8.07%
- Operating Margin
- -4170.14%
- Pretax Margin
- -6747.69%
- Net Profit Margin
- -6523.04%
- EBITDA Margin
- -6590.03%
- EBIT Margin
- -6727.57%
Analyst Forecast
The average price target for Co-Diagnostics is EUR 3.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 3.57
- Price Target Upside
- 30.82% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―